Wright, Hugh
Harris, Patrick N. A.
Chatfield, Mark D.
Lye, David
Henderson, Andrew
Harris-Brown, Tiffany
Donaldson, Anna
Paterson, David L.
Funding for this research was provided by:
Shionogi
Article History
Received: 5 April 2021
Accepted: 24 November 2021
First Online: 7 December 2021
Declarations
:
: Ethical approval was given by The Royal Brisbane and Women’s Hospital HREC. International sites will seek local HREC/IRB approval as per local procedures. This study will be conducted in accordance with the ICH-GCP Guidelines and the principles in the Declaration of Helsinki.
: DLP has received funding from AstraZeneca, Leo Pharmaceuticals, Bayer, GlaxoSmithKline (GSK), Cubist, Venatorx and Accelerate; reports board membership from Entasis, Qpex, Merck, Shionogi, Achaogen, AstraZeneca, Leo Pharmaceuticals, Bayer, GSK, Cubist, Venatorx and Accelerate; reports grants/grants pending from Shionogi and Merck; and has received payment for lectures including service on speaker’s bureaus from Pfizer, outside the submitted work. PNAH has received research grants from MSD, Shionogi and Sandoz, as well as speaker’s fees from Pfizer. All other authors have no competing interests to declare.